AZN · Pharma and healthcare · one day
AstraZeneca (AZN): news on Tuesday 3 November 2026
News from the 24 hours to Tuesday morning, 3 November 2026.
Tone of the day
+7.5strongly positive
+7.5
Relevant headlines28
Stories10
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was dominated by well-received quarterly results, with several brokers raising price targets and the shares jumping. Positive regulatory and trial news added support, while one downgrade, dropped prostate cancer drugs and a whistleblower report were minor negatives.
What drove it
- quarterly results
- broker target upgrades
- regulatory reviews
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Wed 28 Oct | +7.5 | 33 |
| Thu 29 Oct | +2.8 | 13 |
| Fri 30 Oct | +6.3 | 13 |
| Sat 31 Oct | +8.7 | 78 |
| Sun 1 Nov | +6.3 | 8 |
| Mon 2 Nov | +9.2 | 15 |
| Tue 3 Nov | +7.5 | 28 |
10 stories · 28 headlines · strongest first
Pharma and healthcare on 3 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| Brokers raise AstraZeneca targets after results +6.18 headlines today · Citi, RBC, UBS and others raised targets, Barclays kept Buy, while AlphaValue/Baader downgraded to Reduce. | ||
| +9.2 | Broker lifts target as pipeline concerns ease. | |
| +8.3 | Broker keeps buy view and lifts valuation target. | |
| +8.3 | Broker raises target and keeps positive rating. | |
| +8.3 | Broker lifts target citing strong results. | |
| +8.3 | Broker lifts price target meaningfully. | |
| +7.5 | Analyst raises target after results despite timing shift for a drug. | |
| −7.5 | Research house cuts recommendation to a sell-type rating. | |
| +6.7 | Broker maintains positive recommendation. | |
| AstraZeneca Q3 results and $1.5bn savings plan +7.16 headlines today · 80 in all, since 31 October · Coverage reports Q3 revenue up 7%, cost cuts and reassurance on growth. | ||
| +10.0 | Results calm worries about growth and several brokers raise targets. | |
| +8.3 | Investors remain supportive after latest update. | |
| +8.3 | Quarterly sales growth and a broker target increase. | |
| +5.8 | Earnings coverage highlighting its savings drive. | |
| +5.0 | Growth in sales ahead of investor presentations. | |
| +5.0 | Discusses whether earnings and restructuring can support shares. | |
| AstraZeneca medicines used together lengthen survival in lung cancer +5.84 headlines today · 5 in all, since 2 November · Pieces cover the lung cancer filings under EU and Japanese review for Orpathys with Tagrisso. | ||
| +5.8 | Regulators in Europe and Japan accepting lung cancer combination for review. | |
| +5.8 | Overseas regulators examining its lung cancer combination. | |
| +5.8 | Lung cancer therapy filings progressing with regulators. | |
| +1.7 | Company's own commentary on its lung cancer research approach. | |
| AstraZeneca Pharma India gets relief in overcharging case +3.34 headlines today · Delhi High Court stayed the NPPA's ₹151 crore recovery from AstraZeneca Pharma India. | ||
| +3.3 | Court blocks pricing authority action against India subsidiary, a modest relief. | |
| +3.3 | Court halts recovery demand against Indian unit. | |
| +3.3 | Indian unit gets temporary relief in pricing dispute. | |
| +3.3 | Indian unit shielded temporarily from pricing demand. | |
| AstraZeneca shares up 7.02% to $186.65; daily RSI is 75.14 +10.01 headline today · AstraZeneca shares rose 7.02% with high RSI. | ||
| +10.0 | Shares rose sharply on the day. | |
| AstraZeneca gastric cancer drug cuts death risk +9.21 headline today · A report says an AstraZeneca drug lowers the risk of dying from advanced gastric cancer. | ||
| +9.2 | Drug shows survival benefit in advanced stomach cancer. | |
| Whistleblower report on Russian distributors −5.01 headline today · A whistleblower report says big Western drugmakers made payments of millions to distributors in Russia that were tied to fraud. | ||
| −5.0 | Whistleblower report alleges fraud-linked distributor payments by Western drugmakers including it. | |
| AstraZeneca drops two early prostate cancer drugs −5.01 headline today · AstraZeneca has ended development of two prostate cancer drugs that were at an early stage. | ||
| −5.0 | Pipeline pruning as two early prostate cancer candidates are discontinued. | |
| Etcamah pricing in oral SERD market +0.81 headline today · Citeline says Etcamah's price is in line with the oral SERD market. | ||
| +0.8 | Pricing analysis of its oral SERD drug versus competitors, broadly neutral. | |
| Alexion hires head of AI +0.81 headline today · Alexion, part of AstraZeneca, is recruiting a head of AI of its own, though AstraZeneca already has one. | ||
| +0.8 | Subsidiary Alexion recruiting an AI lead, minor organisational item. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.